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As in any other vascularized organ, one of the essentialfunctions of blood vessels in bone is to be a source of O2,
nutrients, hormones, and growth factors.(1) However, additional
roles for bone blood vessels are emerging. For example,
osteoblast precursors have been recently identiﬁed within the
blood vessel wall,(2,3) which suggests that blood vessels are a
source of osteoprogenitors. Moreover, it has been shown that
endothelial cells are specialized niches for hematopoietic stem
cells.(4,5) In light of these ﬁndings, identiﬁcation of the molecular
and cellular mechanisms controlling angiogenesis in bone is
essential to reach a full understanding of how bone and bone
marrow development and homeostasis are regulated.
In this issue of the Journal of Bone and Mineral Research, Zhu
and colleagues(6) report that activating transcription factor‐4
(ATF4) promotes angiogenesis in bone. This effect is associated
with an increased production of vascular endothelial growth
factor A (VEGF‐A) by osteoblasts, and with stabilization of the
hypoxia‐inducible factor 1a (HIF‐1a) in the same cells.(6) It has
been known for quite some time that ATF4 controls bone
homeostasis by stimulating both osteoblastogenesis and
osteoclastogenesis(7–10); now, Zhu and colleagues(6) add a new
element to the picture by showing that mice lacking ATF4 have a
reduced number of blood vessels in bone. The importance of
their study is twofold: ﬁrst, it provides convincing evidence that
ATF4 regulates bone angiogenesis in vivo and ex vivo; and
second, it shows that ATF4 contributes to stabilize HIF‐1a protein
in hypoxic‐like conditions.
The vast majority of adult normal tissues functions at oxygen
(O2) levels between 2% and 9%, with ambient air at 21% O2.
(11)
Cartilage, bone marrow, kidney medulla, and thymus, on the
other hand, can exist at 1%O2 or lower.
(11) When O2 tension goes
below 2%, this condition is considered moderate hypoxia. When
O2 tension goes below 0.5%, hypoxia is considered severe. HIF‐1,
a ubiquitously expressed transcription factor, is a major regulator
of cellular adaptation to hypoxia.(12–18) It is a heterodimeric DNA‐
binding complex that consists of two proteins, HIF‐1a and HIF‐
1b.(19) HIF‐1a is activated when O2 levels drop below 5%
(20–25);
on the other hand, HIF‐1b is non–oxygen responsive. HIF‐1a
does not directly sense variations of O2 tension
(26); a class of
2‐oxoglutarate‐dependent and Fe2þ‐dependent prolyl‐4‐
hydroxylases (PHDs) are the O2 sensors.
(20) PHDs hydroxylate
two prolyl residues (P402 and P564) in the HIF‐1a region referred
to as the O2‐dependent degradation domain.
(27) This modiﬁca-
tion occurs in normoxic conditions and mediates the binding of
the von Hippel–Lindau tumor suppressor protein (pVHL), which
is an E3 ubiquitin ligase, to HIF‐1a. HIF‐1a is then marked with
polyubiquitin chains and targeted for degradation by the
proteasome. Under hypoxic conditions, the activity of the
PHDs is impaired and proline hydroxylation cannot occur. As a
result, HIF‐1a protein accumulates and this initiates a multistep
pathway that includes nuclear translocation of HIF‐1a, dimeriza-
tion with its partner HIF‐1b, recruitment of transcriptional
coactivators, and binding to hypoxia‐responsive elements within
the promoters of hypoxia‐responsive genes.(28)
HIF‐2a, another member of the family, has been recently
identiﬁed and characterized.(17) Similarly to HIF‐1a, HIF‐2a is
degraded by the proteasome in normoxia, whereas it is stabilized
in hypoxia.(17,18) VEGF is one of the direct downstream targets of
both HIF‐1a and HIF‐2a.(17,29)
Despite its high degree of vascularization, a gradient of
oxygenation is present in the bone marrow, and the endosteal
surface of cortical bone is among the most hypoxic areas, as
revealed by staining with the hypoxia marker pimonidazole.(30–
32) This gradient of oxygenation within the bone marrow is most
likely created by the high degree of bone marrow cellularity, the
high levels of O2 consumption by hematopoietic cells, and the
slow ﬂow in the bone marrow sinusoids.(32,33)
Several laboratories are currently investigating how bone cells
and bone blood vessels relate to each other. In particular, it has
been recently shown that either osteoblastic stabilization HIFs or
osteoblastic overexpression of VEGF, one of the most powerful
proangiogenic growth factors, leads to a dramatic increase of
trabecular bone and to a signiﬁcant augmentation of the number
and/or volume of bone marrow blood vessels.(1,18,29,34–36) These
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ﬁndings have prompted researchers to conclude that an
osteogenesis‐angiogenesis coupling is likely to exist and to play
a role in bone development and homeostasis.(18) ATF4 has now
been added to the list of transcription factors that control bone
angiogenesis and, possibly, this osteogenesis‐angiogenesis cou-
pling.(6) Notably, Zhu and colleagues(6) show in their article that
ATF4 not only is sufﬁcient to drive angiogenesis, but is also
necessary to ensure a normal number of blood vessels in bone.
Moreover, they propose, although they do not experimentally
prove, that osteoblastic VEGF downstream of osteoblastic HIF‐1a is
the keymediator of this novel function of ATF4.(6) Increased release
of VEGF from the matrix upon activation of bone resorption by
osteoclasts could be an additional contributing factor.(6)
Taken together, these are interesting and intriguing ﬁndings.
However, because Zhu and colleagues(6) have used the global
knockout of ATF4 for their study rather than its conditional
knockout in cells of the osteoblast lineage, at this stage we
cannot concludewith absolute certainty that osteoblastic ATF4 is
indeed the main factor responsible for the angiogenic pheno-
type observed in mutant mice lacking ATF4. Along these lines,
the activation of osteoclasts and the release of VEGF from
the bone matrix occurring upon universal loss of ATF4 are
probably both osteoblast‐dependent and osteoblast‐indepen-
dent effects.(6)
The notion of an osteogenesis‐angiogenesis coupling, which
would be essential not only in bone development and bone
repair but also in bone homeostasis, is potentially very important.
However, numerous issues still need to be addressed and
resolved. Undoubtedly, all the studies presented and discussed
to this end strongly suggest the existence of a correlation
between osteogenesis and angiogenesis.(1,3,18,29,34,35) Nonethe-
less, although it has been convincingly established that
stabilization of HIFs in cells of the osteoblast lineage or
overexpression of VEGF in the same cells causes a dramatic
increase of bone mass in the trabecular compartment as well as
an augmentation of bone vascularity,(1,18,29,34–36) it has never
been experimentally determined whether the increased number
of blood vessels is an essential prerequisite for the high bone
mass phenotype observed in these models. The same consider-
ation applies to the global knockout of ATF4: loss of ATF4 impairs
both bone mass and bone angiogenesis,(6) but we cannot
unequivocally conclude that the decreased number of blood
vessels is the main factor contributing to the low bone mass
phenotype observed in ATF4‐null bones. Supporting our
concern, it has recently been shown that osteoblastic VEGF
controls osteoblastogenesis mainly through an intracrine
mechanism, rather than by regulating the number of blood
vessels in the bone marrow.(37)
Moreover, it is well established that osteoblasts regulate bone
marrow angiogenesis(18) and that VEGF is a very powerful
proangiogenic factor,(38) but the involvement of additional
cytokines and/or growth factors produced by osteoblasts cannot
be excluded.
In addition, a notion has recently emerged that osteoclasts
could also be angiogenic cells by either producing angiogenic
factors or by releasing them from the bone matrix.(39)
Last, both ATF4 andHIFs are likely to control bone homeostasis
with a variety of mechanisms that go beyond angiogenesis.
In this regard, HIF‐1a is a crucial regulator of glucose
metabolism. In aerobic conditions, glucose is converted to
pyruvate in the cytoplasm. Pyruvate then enters the tricarboxylic
acid (TCA) cycle and oxidative phosphorylation takes place in the
mitochondria.(40) Louis Pasteur was the ﬁrst to record that O2‐
deprived cells convert more glucose to lactate than cells in
normoxic cultures. This is the so‐called “Pasteur effect.” Induction
of the Pasteur effect depends on HIF‐1a, which upregulates
glucose transporters, glycolytic enzymes, and the enzyme lactic
dehydrogenase.(41–43) Moreover, HIF‐1a inhibits mitochondrial
oxidative phosphorylation, at least in part, by augmenting levels
of pyruvate dehydrogenase kinase, an enzyme that phosphor-
ylates and inhibits pyruvate dehydrogenase and thus conversion
of pyruvate into acetyl coenzyme A (CoA).(44,45) By inhibiting the
entry of pyruvate into the mitochondria, HIF‐1a attenuates not
only mitochondrial respiration, but also diminishes reactive
oxygen species (ROS) production in hypoxic cells.(46) Notably, it
has been recently reported that both activation of non‐oxidative
glycolysis and accumulation of ROS signiﬁcantly affect bone
homeostasis,(47–49) which implies that HIFs could indeed control
bonemass at least in part bymodulating glycolysis and oxidative
phosphorylation in osteoblasts.
With respect to ATF4, it has already been unequivocally shown
that ATF4 in osteoblasts activates both gene transcription and
amino acid import, and both functions are crucially important for
ATF4‐dependent regulation of osteoblastogenesis.(7–9)
Notably, ATF4 is a critical mediator of the endoplasmic
reticulum stress response, particularly in hypoxic conditions.(50)
Hypoxia increases ATF4 levels in a HIF‐independent manner(50)
and, at least in part, through inhibition of PHD3 activity.(51) These
ﬁndings indicate that the PHD‐oxygen sensing recruits both HIFs
and ATF4. Zhu and colleagues’ article(6) closes the loop between
hypoxia, ATF4, and HIF‐1a by showing that in cells of the
osteoblast lineage, ATF4 is essential for proper stabilization of
HIF‐1a in hypoxia.(6) The details of this interaction are not yet
clear, though they may again involve the oxygen‐sensing
machinery. In any event, the ﬁnding that HIF‐1a and ATF4
appear to converge on commonO2/nutrient sensing pathways in
higher animals is consistent with the emergence of these two
transcriptional pathways at a similar time in metazoan evolu-
tion.(52,53) Interestingly, RUNX2, another regulator of VEGF
expression,(54) has also been reported to interact with HIF‐1a
and control its stability.(55)
All in all, an interesting feedback mechanism has been
established in which hypoxia increases ATF4 stability in a HIF‐
independent fashion, and this leads to further stabilization of
HIF‐1awith modalities that need to be further elucidated. At this
stage, it is unknown whether this novel loop occurs only in
osteoblastic cells, or whether it is indeed a more general
mechanism of HIF‐1a regulation also present in other cell types.
Moreover, it is unknown whether stabilization of HIF‐2a in
hypoxia requires interaction with ATF4.
Disclosures
All authors state that they have no conﬂicts of interest.
Journal of Bone and Mineral Research ATF4 AND HIF‐1a IN BONE: AN INTRIGUING RELATIONSHIP 1867
Acknowledgments
This work was supported by the NIH (RO1 AR04819 to ES) and by
the People Programme (Marie Curie Actions) of the European
Union’s Seventh Framework Programme (FP7/2007‐2013) under
the Research Executive Agency grant agreement (300388 to CM).
Authors’ roles: All of the authors contributed to the writing of
this manuscript.
References
1. Schipani E, Maes C, Carmeliet G, Semenza GL. Regulation of
osteogenesis‐angiogenesis coupling by HIFs and VEGF. J Bone
Miner Res. 2009;24(8):1347–53.
2. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I,
Tagliafico E, Ferrari S, Robey PG, Riminucci M, Bianco P. Self‐
renewing osteoprogenitors in bone marrow sinusoids can organize
a hematopoietic microenvironment. Cell. 2007;131(2):324–36.
3. Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, Mackem S,
Carmeliet G, Kronenberg HM. Osteoblast precursors, but not mature
osteoblasts, move into developing and fractured bones along with
invading blood vessels. Dev Cell. 2010;19(2):329–44.
4. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid
progenitors occupy distinct bone marrow niches. Nature.
2013;495(7440):231–5.
5. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family
receptors distinguish hematopoietic stem and progenitor cells and
reveal endothelial niches for stem cells. Cell. 2005;121(7):1109–21.
6. Zhu K, Jiao H, Li S, Cao H, Galson DL, Zhao Z, Zhao X, Lai Y, Fan J, Im
HJ, Chen D, Xiao G. ATF4 promotes bone angiogenesis by increasing
VEGF expression and release in the bone environment. J Bone
Miner Res. 2013;28:1870–1884.
7. Karsenty G. Transcriptional control of skeletogenesis. Annu Rev
Genomics Hum Genet. 2008;9:183–96.
8. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L,
Brancorsini S, Sassone‐Corsi P, Townes TM, Hanauer A, Karsenty G.
ATF4 is a substrate of RSK2 and an essential regulator of osteoblast
biology; implication for Coffin‐Lowry Syndrome. Cell .
2004;117(3):387–98.
9. Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada
LF, Karsenty G. ATF4 mediation of NF1 functions in osteoblast
reveals a nutritional basis for congenital skeletal dysplasiae. Cell
Metab. 2006;4(6):441–51.
10. Cao H, Yu S, Yao Z, Galson DL, Jiang Y, Zhang X, Fan J, Lu B, Guan Y,
Luo M, Lai Y, Zhu Y, Kurihara N, Patrene K, Roodman GD, Xiao G.
Activating transcription factor 4 regulates osteoclast differentiation
in mice. J Clin Invest. 2010;120(8):2755–66.
11. Simon MC, Keith B. The role of oxygen availability in embryonic
development and stem cell function. Nat Rev Mol Cell Biol.
2008;9(4):285–96.
12. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to
hypoxia. Physiol Rev. 1996;76(3):839–85.
13. Giaccia A, Siim B, Johnson R. HIF‐1 as a target for drug development.
Nat Rev Drug Discov. 2003;2:803–11.
14. Kaelin WG Jr. How oxygen makes its presence felt. Genes Dev.
2002;16(12):1441–5.
15. Liu L, Simon MC. Regulation of transcription and translation by
hypoxia. Cancer Biol Ther. 2004;3(6):492–7.
16. Semenza GL. Targeting HIF‐1 for cancer therapy. Nat Rev Cancer.
2003;3(10):721–32.
17. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling
rivalry in hypoxic tumour growth and progression. Nature reviews.
Cancer. 2011;12(1):9–22.
18. Maes C, Carmeliet G, Schipani E. Hypoxia‐driven pathways in bone
development, regeneration and disease. Nat Rev Rheumatol.
2012;8(6):358–66.
19. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia‐inducible factor 1
is a basic‐helix‐loop‐helix‐PAS heterodimer regulated by cellular O2
tension. Proc Natl Acad Sci U S A. 1995;92(12):5510–4.
20. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and
approaches to enforce tumour regress ion . Nature .
2006;441(7092):437–43.
21. Chan D, Sutphin P, Denko N, Giaccia A. Role of prolyl hydroxylation
in oncogenically stabilized hypoxia‐inducible factor‐1alpha. J Biol
Chem. 2002;277:40112–7.
22. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara J,
Lane W, Kaelin W. HIFalpha targeted for VHL‐mediated destruction
by proline hydroxylation: implications for O2 sensing. Science.
2001;292:464–8.
23. Jaakkola P, Mole D, Tian Y, Wilson M, Gielbert J, Gakell S, Kriegsheim
A, Heberstreit H, Mukherji M, Schofield C, Maxwell P, Ratcliffe P.
Targeting of HIF‐alpha to the von Hippel‐Lindau ubiquitylation
complex by O2‐regulated prolyl hydroxylation. Science.
2001;292:468–72.
24. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP.
Structure of an HIF‐1alpha‐pVHL complex: hydroxyproline recogni-
tion in signaling. Science. 2002;296:1886–9.
25. Wang GL, Semenza GL. General involvement of hypoxia‐inducible
factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U
S A. 1993;90(9):4304–8.
26. Chan D, Sutphin P, Yen S, Giaccia A. Coordinate regulation of the
oxygen‐dependent degradation domains of hypoxia‐inducible
factor 1 alpha. Mol Cell Biol. 2005;25:6415–26.
27. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF
prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐
state levels of HIF‐1alpha in normoxia. EMBO J. 2003;22(16):4082–
90.
28. Kallio PJ, Wilson WJ, O’Brien S, Makino Y, Poellinger L. Regulation of
the hypoxia‐inducible transcription factor 1alpha by the ubiquitin‐
proteasome pathway. J Biol Chem. 1999;274(10):6519–25.
29. Maes C, Araldi E, Haigh K, Khatri R, Van Looveren R, Giaccia AJ,
Haigh JJ, Carmeliet G, Schipani E. VEGF‐independent cell‐autono-
mous functions of HIF‐1alpha regulating oxygen consumption in
fetal cartilage are critical for chondrocyte survival. J Bone Miner Res.
2012;27(3):596–609.
30. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of
hematopoietic stem cells in the bone marrow according to regional
hypoxia. Proc Natl Acad Sci U S A. 2007;104(13):5431–6.
31. Winkler IG, Barbier V, Wadley R, Zannettino AC, Williams S, Levesque
JP. Positioning of bone marrow hematopoietic and stromal cells
relative to blood flow in vivo: serially reconstituting hematopoietic
stem cells reside in distinct nonperfused niches. Blood.
2010;116(3):375–85.
32. Rankin EB, Giaccia AJ, Schipani E. A central role for hypoxic signaling
in cartilage, bone, and hematopoiesis. Curr Osteoporos Rep.
2011;9(2):46–52.
33. Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO(2)
distributions in the bone marrow hematopoietic compartment. I.
Krogh’s model. Biophys J. 2001;81(2):675–84.
34. Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, Bouxsein ML,
Faugere MC, Guldberg RE, Gerstenfeld LC, Haase VH, Johnson RS,
Schipani E, Clemens TL. The hypoxia‐inducible factor alpha pathway
couples angiogenesis to osteogenesis during skeletal development.
J Clin Invest. 2007;117(6):1616–26.
35. Rankin EB, Wu C, Khatri R, Wilson TL, Andersen R, Araldi E, Rankin
AL, Yuan J, Kuo CJ, Schipani E, Giaccia AJ. The HIF signaling pathway
in osteoblasts directly modulates erythropoiesis through the
production of EPO. Cell. 2012;149(1):63–74.
1868 SCHIPANI ET AL. Journal of Bone and Mineral Research
36. Maes C, Goossens S, Bartunkova S, Drogat B, Coenegrachts L,
Stockmans I, Moermans K, Nyabi O, Haigh K, Naessens M,
Haenebalcke L, Tuckermann JP, Tjwa M, Carmeliet P, Mandic V,
David JP, Behrens A, Nagy A, Carmeliet G, Haigh JJ. Increased
skeletal VEGF enhances beta‐catenin activity and results in
excessively ossified bones. EMBO J. 2010;29(2):424–41.
37. Liu Y, Berendsen AD, Jia S, Lotinun S, Baron R, Ferrara N, Olsen BR.
Intracellular VEGF regulates the balance between osteoblast and
adipocyte differentiation. J Clin Invest. 2012;122(9):3101–13.
38. Zelzer E, Olsen BR. Multiple roles of vascular endothelial growth
factor (VEGF) in skeletal development, growth, and repair. Curr
Topics Dev Biol. 2005;65:169–87.
39. Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD,
Windle JJ, Blair HC, Roodman GD. Osteoclasts are important for
bone angiogenesis. Blood. 2010;115(1):140–9.
40. Weidemann A, Johnson RS. Biology of HIF‐1alpha. Cell Death Differ.
2008;15(4):621–7.
41. Seagroves T, Johnson R. Two HIFs may be better than one. Cancer
Cell. 2002;1:211–3.
42. Iyer N, Kotch L, Agani F, Leung S, Laughner E, Wenger R, Gassmann
M, Gearhart J, Lawler A, Yu A, Semenza G. Cellular and
developmental control of O2 homeostasis by hypoxia‐inducible
factor 1alpha. Genes Dev. 1998;12:149–62.
43. Seagroves T, Ryan H, Lu H, Routers B, Knapp M, Thibault P,
Laderoute K, Johnson R. Transcription factor HIF‐1 is necessary
mediator of the Pasteur effect in mammalian cells. Mol Cell Biol.
2001;21:3436–44.
44. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF‐1
mediates adaptation to hypoxia by actively downregulating
mitochondrial oxygen consumption. Cell Metab. 2006;3(3):187–97.
45. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF‐1‐mediated
expression of pyruvate dehydrogenase kinase: a metabolic switch
required for cellular adaptation to hypoxia. Cell Metab.
2006;3(3):177–85.
46. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF‐
1 regulates cytochrome oxidase subunits to optimize efficiency of
respiration in hypoxic cells. Cell. 2007;129(1):111–22.
47. Esen E, Chen J, Karner CM, Okunade AL, Patterson BW, Long F. WNT‐
LRP5 Signaling induces Warburg effect through mTORC2 activation
during osteoblast differentiation. Cell Metab. 2013;17(5):745–55.
48. Rached MT, Kode A, Xu L, Yoshikawa Y, Paik JH, Depinho RA,
Kousteni S. FoxO1 is a positive regulator of bone formation by
favoring protein synthesis and resistance to oxidative stress in
osteoblasts. Cell Metab. 2010;11(2):147–60.
49. Ambrogini E, Almeida M, Martin‐Millan M, Paik JH, Depinho RA, Han L,
Goellner J, Weinstein RS, Jilka RL, O’Brien CA, Manolagas SC. FoxO‐
mediated defense against oxidative stress in osteoblasts is indispens-
able for skeletal homeostasis in mice. Cell Metab. 2010;11(2):136–46.
50. Ye J, Koumenis C. ATF4, an ER stress and hypoxia‐inducible
transcription factor and its potential role in hypoxia tolerance and
tumorigenesis. Curr Mol Med. 2009;9(4):411–6.
51. Koditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, Franke C,
Myllyharju J, Wenger RH, Katschinski DM. Oxygen‐dependent ATF‐4
stability is mediated by the PHD3 oxygen sensor. Blood.
2007;110(10):3610–7.
52. Ferreira TC, Hertzberg L, Gassmann M, Campos EG. The yeast
genome may harbor hypoxia response elements (HRE). Comp
Biochem Physiol C Toxicol Pharmacol. 2007;146(1–2):255–63.
53. Yokoyama T, Nakamura T. Tribbles in disease: signaling pathways
important for cellular function and neoplastic transformation.
Cancer Sci. 2011;102(6):1115–22.
54. Zelzer E, GlotzerDJ, HartmannC, ThomasD, FukaiN, Soker S, OlsenBR.
Tissue specific regulation of VEGF expression during bone develop-
ment requires Cbfa1/Runx2. Mech Dev. 2001;106(1–2):97–106.
55. Kwon TG, Zhao X, Yang Q, Li Y, Ge C, Zhao G, Franceschi RT. Physical
and functional interactions between Runx2 and HIF‐1alpha induce
vascular endothelial growth factor gene expression. J Cell Biochem.
2011;112(12):3582–93.
Journal of Bone and Mineral Research ATF4 AND HIF‐1a IN BONE: AN INTRIGUING RELATIONSHIP 1869
